Good bacteria that protects against HIV identified

Image
Press Trust of India Houston
Last Updated : Mar 30 2014 | 1:10 PM IST
Scientists have for the first time grown vaginal skin cells outside the body to better identify the good bacteria that protect women from HIV infection and other sexually transmitted diseases.
Researchers at the University of Texas Medical Branch at Galveston and the Oak Crest Institute of Science in Pasadena, California, set out to study the relationship between the skin cells and the "good" bacteria.
The health of the human vagina depends on a symbiotic/mutually beneficial relationship with "good" bacteria that live on its surface feeding on products produced by vaginal skin cells.
These good bacteria, in turn, create a physical and chemical barrier to bad bacteria and viruses including HIV.
The researchers are the first to grow human vaginal skin cells in a dish in a manner that creates surfaces that support colonisation by the complex good and bad communities of bacteria collected from women during routine gynecological exams.
The bacteria communities have never before been successfully grown outside a human.
By using this model of the human vagina, researchers discovered that certain bacterial communities alter the way HIV infects and replicates.
Their laboratory model will allow careful and controlled evaluation of the complex community of bacteria to ultimately identify those species that weaken the defenses against HIV.
The research group led by Richard Pyles at UTMB also indicated that this model "will provide the opportunity to study the way that these mixed species bacterial communities change the activity of vaginal applicants including over-the-counter products like douches and prescription medications and contraceptives."
The team documented the potential for their system to better evaluate current and future antimicrobial drugs in terms of how they interact with "good and bad" bacteria.
In their current studies a bacterial community associated with a symptomatic condition called bacterial vaginosis substantially reduced the antiviral activity of one of the leading anti-HIV medicines.
Conversely, vaginal surfaces occupied by healthy bacteria and treated with the antiviral produced significantly less HIV than those vaginal surfaces without bacteria treated with the same antiviral.
The study was published in the journal PLOS One.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 30 2014 | 1:10 PM IST

Next Story